How can iron salts mediate the degradation of nucleos(t)ides by elliptinium acetate via free-radicals?
Elliptinium acetate (NSC 264137) is an antineoplastic agent currently used in anticancer chemotherapy. We report here the first evidence that this drug is able to modify DNA models via a redox process with iron salts. In presence of iron (III) salts, EDTA and H2O2, 9-OH-NME degrades deoxyguanosine. The two main products are guanine and 8-hydroxydeoxyguanosine which result from the formation of hydroxyl radicals. The biological implications of this phenomenon are briefly discussed.
D000470:Alkaloids / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004264:DNA Topoisomerases, Type I / Q000502:physiology; D004611:Ellipticines / Q000494:pharmacology*; D006801:Humans; D006878:Hydroxides; D017665:Hydroxyl Radical; D007501:Iron / Q000494:pharmacology*; D009705:Nucleosides / Q000378:metabolism*; D009711:Nucleotides / Q000378:metabolism*
D000470:Alkaloids; D000970:Antineoplastic Agents; D004611:Ellipticines; D006878:Hydroxides; D009705:Nucleosides; D009711:Nucleotides; C027767:elliptinium; D017665:Hydroxyl Radical; D007501:Iron; D004264:DNA Topoisomerases, Type I